ReviewDrugs2014
Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases.
Review in Drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00699751 (A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Who cites it
16 citing papers in PubMed, 41 citations in OpenAlex.
- Effect of intratumoral alpha radiation on tumor growth delay and tumor microenvironment in an orthotopic colorectal liver metastasis murine model.Scientific reports · 2026Article
- Diffusing alpha-emitters radiation therapy: In vivo measurements of effective diffusion and clearance rates across multiple tumor types.Medical physics · 2025Article
- Stereotactic implantation of diffusing alpha-emitters radiation therapy sources in the swine brain: a potential new focal therapy for brain tumors.Journal of neuro-oncology · 2025Article
- Theranostics and Patient-Specific Dosimetry.Seminars in radiation oncology · 2023Review
- Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.Journal of hematology & oncology · 2022Review
- FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021.Molecules (Basel, Switzerland) · 2022Review
- Atomic Nanogenerators in Targeted Alpha Therapies: Curie's Legacy in Modern Cancer Management.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.Cancer biotherapy & radiopharmaceuticals · 2018Article
- Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Review
- Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons.Clinical & experimental metastasis · 2017Review
- Radium-223 dichloride in clinical practice: a review.European journal of nuclear medicine and molecular imaging · 2016Review
- Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases.Annals of nuclear medicine · 2016Article
- [Bone metastases : New aspects of pathogenesis and systemic therapy].Der Internist · 2016Review
- The best of both worlds - managing the cancer, saving the bone.Nature reviews. Endocrinology · 2016Review
- Cancer-targeted therapies and radiopharmaceuticals.BoneKEy reports · 2015Review
- Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.Expert opinion on drug delivery · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radium-223 dichloride (Xofigo®; formerly Alpharadin™) [hereafter referred to as radium-223] is a first-in-class alpha particle-emitting radiopharmaceutical that has recently been approved for the treatment of patients with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease. Radium-223 is a calcium mimetic, which targets bone, delivering cytotoxic radiation to the sites of bone metastases. In the recently reported Alpharadin™ in Symptomatic Prostate Cancer (ALSYMPCA) phase III study, radium-223 was associated with significantly improved overall survival compared with placebo, making it the first bone-targeted CRPC therapy for which an overall survival benefit has been demonstrated. The ALSYMPCA study also demonstrated the beneficial effects of radium-223 on disease-related symptomatic skeletal events, pain and health-related quality of life. Radium-223 was generally well tolerated, being associated with low rates of myelosuppression and generally mild gastrointestinal adverse events. Thus, radium-223 is a valuable addition to the treatment options for this poor-prognosis population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.